Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
Business Wire•16/11/2026•08:00 ET
0
Key Highlights
- ➤Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront
- ➤OLN324 is a Phase 3 bispecific antibody targeting VEGF and Ang2
- ➤Deal includes up to approximately $1.125 billion in regulatory and commercial milestones
- ➤Blackstone will provide $750 million to fully fund OLN324’s Phase 3 development
- ➤Transaction is expected to close before the end of 2026, subject to approvals
Expert Statements
Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson
“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control”
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
* Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema
Get started
Create a free account to read the full story.
